ADA Completes First Living Guideline, Keeping Biopsy Central to Oral Cancer Detection

Edited by Dentaltown staff

The ADA has published the final recommendations of its first living guideline, completing a four-part update on oral cancer detection. The guideline keeps the clinical examination and biopsy at the center of care and recommends against substituting adjunctive tests for either.

The final installment, covering salivary adjuncts, was published online Sept. 28 ahead of print in The Journal of the American Dental Association. Earlier installments this year addressed cytology, vital staining, and light-based adjuncts.

Across the series, the guideline states that adjunctive tests should not replace an indicated biopsy or referral. It generally recommends against their routine use to decide on biopsy or referral in adults with clinically evident oral lesions, and against using them to screen asymptomatic adults without lesions. Cytology may be offered in limited circumstances when a biopsy is not possible, advisable, or indicated.

For salivary tests, the panel found no eligible evidence on the diagnostic accuracy of the tests commercially available in the U.S. It issued research-only recommendations, meaning the tests should be used only in research settings. According to the guideline, none of those tests has been cleared or approved by the FDA. The panel said policy makers should not endorse the tests through coverage decisions or public health programs until adequate research evidence is available.

Clinicians should obtain updated medical, social, and dental histories and perform a comprehensive extraoral and intraoral examination on all adult patients. A punch or scalpel biopsy followed by histopathological assessment remains the preferred and definitive diagnostic method.

Highly suspicious lesions should be biopsied or referred promptly, without a waiting period. For lesions under watchful waiting, clinicians should recommend biopsy or referral if the lesion does not resolve 10–14 days after initial evaluation and there is no definitive diagnosis or treatment plan. If a lesion persists or progresses despite a negative cytology result, clinicians should immediately biopsy or refer.

Shelley Olson, chair of the ADA Council on Dental Benefit Programs, said payers should cover that 10–14 day follow-up without frequency limitations, because the visit is driven by a previously identified condition rather than a routine exam schedule. She advised coding the visit according to the services performed and documented.

“Dental visits can save lives,” said panel chair Mark Lingen of the University of Chicago Medicine. The ADA developed the guideline with methodologists from the Center for Integrative Global Oral Health at the University of Pennsylvania School of Dental Medicine and an expert multidisciplinary panel, with oversight from the ADA Council on Scientific Affairs.

The guideline updates the ADA’s 2017 recommendations on potentially malignant disorders and oral cancer, and will be revised as new evidence emerges. Learning and engagement related to the ADA Living Guideline Program are supported in part by an unrestricted grant from Colgate Oral Pharmaceuticals.

Sources:
The Journal of the American Dental Association, “Living evidence-informed guideline on the early detection of oral squamous cell carcinoma and potentially malignant disorders: Salivary adjunct tests to determine the need for biopsy, Version 2026 1.0,” published online Sept. 28, 2026: jada.ada.org/article/S0002-8177(26)00528-3
ADA News, “First ADA living guideline reaffirms dental exams crucial to detecting oral cancer early,” Sept. 28, 2026: adanews.ada.org/2026/september/first-ada-living-guideline
American Dental Association, Oral Cancer Guideline (2026 Update): ada.org/oral-cancer-guideline